ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BCTXW BriaCell Therapeutics Corporation

0.2999
0.00 (0.00%)
Last Updated: 09:30:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.2251
Ask Price 0.30
News -
Company Name Stock Ticker Symbol Market Type
BriaCell Therapeutics Corporation BCTXW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.2999 09:30:01
Open Price Low Price High Price Close Price Prev Close
0.2999
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0  0.2999 USD

BriaCell Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.79M 15.98M - 0 -20.3M -1.27 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News BriaCell Therapeutics

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BCTXW Message Board. Create One! See More Posts on BCTXW Message Board See More Message Board Posts

BCTXW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.

Your Recent History

Delayed Upgrade Clock